This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
One of the key risk factors for colorectal cancer is inflammatory bowel disease, like Crohn’s disease and ulcerative colitis. These diseases are driven by chronic inflammatory responses to the gut microbiome and are associated with dysbiotic changes in the microbiome composition. Dr. Duncan-Lowey’s study will focus on understanding the molecular interactions between gut microbes and human hosts and defining how these interactions are different between healthy people and patients with inflammatory bowel disease. Understanding these differences can help define what changes in the microbiome may cause inflammation, and how changes in the intestinal layers may change which microbes are able to reside in the gut. These insights can lead to a new understanding of to how to treat inflammatory bowel disease and mitigate inflammation to decrease the risk of colorectal cancer.
Yale University | All Cancers | 2022 | Noah Palm, Ph.D.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).